Ticker

STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results  Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for subcutaneous initiation treatment in the US Leqembi was approved in Brazil and Canada Leqembi was approved for IV maintenance treatment in the United Kingdom Eisai submitted…

Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript

NEW YORK & TOKYO--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology…

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.

Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript